| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3348313 | Diagnostic Microbiology and Infectious Disease | 2008 | 4 Pages |
Abstract
We evaluated the impact of piperacillin/tazobactam (PT) therapy on galactomannan enzyme immunoassay (GEI) testing (Platelia™; Bio-Rad, Marnes La Coquette, France). Galactomannan contents of PT batches were highly variable. We found that false-positive GEI results can be avoided by performance of blood sampling before PT administration and by using separate sites for blood sampling and for administration of antibiotics.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Olaf Penack, Patricia Rempf, Barbara Graf, Eckhard Thiel, Igor Wolfgang Blau,